Sanguine Corporation Adds to its Management Advisory Team
6:00 AM ET - BusinessWire
Sanguine Corporation (OTC Bulletin Board: SGNC) is pleased to announce the selection of Gary L. Corderman to the Company's Management Advisory team. Mr. Corderman has over 20 years of investment experience. Corderman joined Halbert, Hargrove/Russell LLC, located in Long Beach, California in 1998. He has built his practice and service team with a focus on working with both institutional sized family/trust accounts (many of which are multi-generational) and other investment accounts that have a fiduciary nature, such as pension plans and endowment or foundation relationships.
Previously Mr. Corderman worked extensively with consulting and marketing teams that focused on both institutional as well as individual accounts. He spent time most recently with Lord Abbett Mutual Funds but also Watson Wyatt Consulting and Fidelity Investments Institutional. His duties have included a broad range of responsibilities from working directly on individual and institutional client relationships to public speaking engagements. He was also responsible for instructing and educating brokers and account executives at brokerage firms about structuring portfolios for institutional clients. Mr. Corderman received his Bachelor's degree in Business Management from Miami University and his Master of Business Administration from the Fuqua School of Business at Duke University.
Dr. Thomas C. Drees, Ph.D., CEO, added, "We continue to build our management team with talent in the areas of finance, investment and healthcare. As we continue to execute our strategy of building a company focused on long-term growth opportunities, we look toward Gary as becoming an integral part of our ability to garner Institutional support. We expect Gary's experience will aid significantly with our previously announced acquisition strategies."
About Sanguine
Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on the development of an oxygen-carrying synthetic substitute for human red blood cells and various other areas requiring oxygen profusion. The company is developing a synthetic red blood cell product, PHER-O2 that consists of perfluoro-decalin molecules, purified water, and a proprietary synthetic - patent pending fluorinated surfactant to hold the emulsion together.
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
For Sanguine Corporation Michael Dancy, 801-746-3570 (Investor Relations) medancy@allwest.net
Recent Market News
May 2, 2008
invest at your own risk, based on your own due diligence, at your own risk tolerance
